Evidence map›Paper›PMID 31333565›Full record

ArticleFrontiers in neurology2019

International Guidelines for the Treatment of Huntington's Disease.

Anne-Catherine Bachoud-Lévi, Joaquim Ferreira, Renaud Massart, Katia Youssov, Anne Rosser, Monica Busse, David Craufurd, Ralf Reilmann, Giuseppe De Michele, Daniela Rae and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 101 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
101citing papers in PubMed, 8 pooled it
9.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

101 citing papers in PubMed, 8 syntheses or guidelines pooled it, 188 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Systemic Symptoms in Huntington's Disease: A Comprehensive Review.Movement disorders clinical practice · 2024
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Article
  13. Article
  14. Article
  15. Review
  16. Frontiers in bioinformatics · 2026
    Article
  17. Article
  18. Review
  19. Article
  20. Article

41 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 14 institutions in 8 countries.

Anne-Catherine Bachoud-LéviNational Centre of Reference for Huntington's Disease, Henri Mondor Hospital, AP-HP, Creteil & NeurATRIS, Créteil, France.
Joaquim FerreiraClinical Pharmacology Unit, Instituto de Medicina Molecular, Lisbon, Portugal.
Renaud MassartNational Centre of Reference for Huntington's Disease, Henri Mondor Hospital, AP-HP, Creteil & NeurATRIS, Créteil, France.
Katia YoussovNational Centre of Reference for Huntington's Disease, Henri Mondor Hospital, AP-HP, Creteil & NeurATRIS, Créteil, France.
Anne RosserIPMCN, School of Medicine, Cardiff University, Cardiff, United Kingdom.
Monica BusseCentre for Trials Research, Cardiff University, Cardiff, United Kingdom.
David CraufurdDivision of Evolution and Genomic Sciences, Faculty of Biology, Medicine and Health, Manchester Centre for Genomic Medicine, School of Biological Sciences, University of Manchester, Manchester, United Kingdom.
Ralf ReilmannDepartment of Radiology, George-Huntington-Institute, Universitaetsklinikum Muenster, Münster, Germany.
Giuseppe De MicheleDepartment of Neurosciences, Federico II University, Naples, Italy.
Daniela RaeDepartment of Clinical Genetics, NHS Grampian, Aberdeen, United Kingdom.
Ferdinando SquitieriHuntington and Rare Diseases Unit, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.
Klaus SeppiDepartment of Neurology, Medical University Innsbruck, Innsbruck, Austria.
Charles PerrineGenetic Department, National Center of reference for Huntington's Disease, Salpêtrière Hospital, Paris, France.
Clarisse Scherer-GagouNeurology Department, Angers University Hospital, Angers, France.
Olivier AudreyNeurology Department, Angers University Hospital, Angers, France.
Christophe VernyNeurology Department and UMR CNRS 6214 INSERM U1083, National Centre of Reference for Neurodegenerative Diseases, Angers University Hospital, Angers, France.
Jean-Marc BurgunderNeuroZentrumSiloah and Department of Neurology, Swiss HD Center, University of Bern, Bern, Switzerland.
Cardiff University · GBCentre Hospitalier Universitaire Henri-Mondor · FRUniversité d'Angers · FRAssistance Publique – Hôpitaux de Paris · FRCentre National de la Recherche Scientifique · FRHertie Institute for Clinical Brain Research · DEInnsbruck Medical University · ATIstituti di Ricovero e Cura a Carattere Scientifico · ITManchester University NHS Foundation Trust · GBNational Legal Medicine Institute · PTNHS Grampian · GBSorbonne Université · FRUniversity of Bern · CHUniversity of Naples Federico II · IT

Funding

HCRW_ NIHR-FS-2012Medical Research Council G0801418Medical Research Council G9810900Medical Research Council MR/L010305/1
6 · The paper itself

Abstract

The European Huntington's Disease Network (EHDN) commissioned an international task force to provide global evidence-based recommendations for everyday clinical practice for treatment of Huntington's disease (HD). The objectives of such guidelines are to standardize pharmacological, surgical and non-pharmacological treatment regimen and improve care and quality of life of patients. A formalized consensus method, adapted from the French Health Authority recommendations was used. First, national committees (French and English Experts) reviewed all studies published between 1965 and 2015 included dealing with HD symptoms classified in motor, cognitive, psychiatric, and somatic categories. Quality grades were attributed to these studies based on levels of scientific evidence. Provisional recommendations were formulated based on the strength and the accumulation of scientific evidence available. When evidence was not available, recommendations were framed based on professional agreement. A European Steering committee supervised the writing of the final recommendations through a consensus process involving two rounds of online questionnaire completion with international multidisciplinary HD health professionals. Patients' associations were invited to review the guidelines including the HD symptoms. Two hundred and nineteen statements were retained in the final guidelines. We suggest to use this adapted method associating evidence base-medicine and expert consensus to other rare diseases.

Indexed as

careclinical practiceguidelinesHuntington's diseasetreatment

Identifiers

PMID31333565
PMCPMC6618900
OpenAlexW2949587997

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.